Alvelestat (MPH966)
Phase 2CompletedDevelopment Stage
Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
Apr 8, 2019 → Dec 1, 2023
About Alvelestat (MPH966)
Alvelestat (MPH966) is a phase 2 stage product being developed by Mereo BioPharma for Alpha-1 Antitrypsin Deficiency (AATD). The current trial status is completed. This product is registered under clinical trial identifier NCT03679598. Target conditions include Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD.
What happened to similar drugs?
0 of 2 similar drugs in Alpha-1 Antitrypsin Deficiency (AATD) were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03679598 | Phase 2 | Completed |
Competing Products
13 competing products in Alpha-1 Antitrypsin Deficiency (AATD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) Placebo | Novartis | Phase 2 | 27 |
| VX-668 + Placebo | Vertex Pharmaceuticals | Phase 1 | 29 |
| VX-864 | Vertex Pharmaceuticals | Phase 2 | 27 |
| ALN-AAT02 + Placebo + ALN-AAT02 | Alnylam Pharmaceuticals | Phase 1/2 | 21 |
| ARC-AAT Injection + Diphenhydramine | Arrowhead Pharmaceuticals | Phase 1 | 18 |
| ARC-AAT Injection | Arrowhead Pharmaceuticals | Phase 2 | 24 |
| Alpha-1 MP | Grifols | Phase 3 | 44 |
| Alpha-1 MP | Grifols | Phase 3 | 41 |
| WVE-006 | WaVe Life Sciences | Phase 1 | 23 |
| WVE-006 | WaVe Life Sciences | Phase 1/2 | 33 |
| INBRX-101/rhAAT-Fc | Inhibrx Biosciences | Phase 1 | 23 |
| Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mg | Kamada | Phase 2 | 29 |
| KRRO-110 | Korro Bio | Phase 1/2 | 26 |